Answers are grounded in this paper and cite their sources.
The incidence of inflammatory bowel disease (IBD) among the elderly in Canada has increased from 1 out of 160 seniors in 2018, to 1 out of 88 seniors in 2023, representing 1.14% of the senior population. It is thought that more than one-third of all IBD patients will be over 60 years of age in the next decade. The prevalence is expected to increase due to a combination of new diagnoses as well as the aging of younger people already living with IBD. Elderly persons with IBD face unique challenges that younger people with IBD often do not, such as co-existing comorbidities, frailty, polypharmacy, and an increased risk of infections and cancer. While the therapeutic management of elderly persons with IBD is similar to that of younger people with IBD, it requires careful consideration of many different factors, and special attention is needed when weighing the risks and benefits of medical therapy.
No takes yet. Share an insight, caveat, or question.
Seth R. Shaffer (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: